Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5729312 | 0.97 | PTGS1 (0.34) | PTGS1MEN1KMT2ATSHR | |
| SCHEMBL5729587 | 0.94 | ALDH1A1 (0.38) | PTGS1MEN1KMT2AALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL6311267 | 0.93 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1LMNAPKM | |
| SCHEMBL5731066 | 0.90 | PTGS1 (0.34) | PTGS1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL5729286 | 0.88 | PTGS1 (0.34) | PTGS1ALDH1A1 | |
| SCHEMBL6307449 | 0.87 | PTGS1 (0.35) | PTGS1ALDH1A1 | |
| SCHEMBL5730364 | 0.86 | MEN1 (0.35) | PTGS1MEN1KMT2ATSHRCHRNB4 | |
| SCHEMBL6304492 | 0.86 | MLLT1 (0.34) | PTGS1CHRNB4CHRNA3ALDH1A1 | |
| SCHEMBL5729513 | 0.84 | SLC6A2 (0.37) | PTGS1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL5729633 | 0.84 | SLC6A2 (0.37) | PTGS1MEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1102755-B1 | SUBSTITUTED ISOXAZOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORP (US) | 2006-01-04 | — | — | EP | disclosed |
| US-6869969-B2 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2005-03-22 | — | — | US | disclosed |
| US-6743815-B2 | OSTEOPOROSIS; ENDOMETRIOSIS; ALZHEIMER'S DISEASE | CHIRON CORPORATION | 2004-06-01 | — | — | US | disclosed |
| US-20040102498-A1 | Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors | CHIRON CORPORATION | 2004-05-27 | — | — | US | disclosed |
| US-20030065012-A1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2003-04-03 | — | — | US | disclosed |
| US-6387920-B2 | ISOXAZOLE COMPOUNDS; FOR TREATING ESTROGEN RECEPTOR-MEDIATED DISORDERS SUCH AS OSTEOPOROSIS, BREAST AND ENDOMETRIAL CANCERS, ATHEROSCLEROSIS, ALZHEIMER'S DISEASE | CHIRON CORPORATION | 2002-05-14 | — | — | US | disclosed |
| US-20010036956-A1 | Estrogen receptor modulators | HUEBNER VERENA D (US) | 2001-11-01 | — | — | US | disclosed |
| US-6262098-B1 | ISOXAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST | CHIRON CORPORATION | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036956-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | PTGS1 588/4885MEN1 2458/4885KMT2A 2788/4885 |
| US-20030065012-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | PTGS1 588/4885MEN1 2458/4885KMT2A 2788/4885 |
| US-20040102498-A1 | Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors | ESR2, GPER1, ESR1 | PTGS1 413/4885MEN1 1663/4885KMT2A 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.